Mode of action

Belinostat belongs to a class of anti-cancer agents, HDACi, which by enzymatic process (acetylation) works to normalize the abnormal gene function pattern characteristic of cancer cells.

Belinostat is a strong member of the HDACi group as it:

• Has demonstrated anti-cancer activity against a variety of human tumors
• Is well-tolerated with minimal or no impact on bone marrow function
• Can be administered both by infusion and orally